

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to Shanghai Junshi Biosciences Co., Ltd.: Announcement on Release of Lock-up for Domestic Shares dated 24 June 2019 published by Shanghai Junshi Biosciences Co., Ltd. on the website of the National Equities Exchange and Quotations. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 24 June 2019

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive Directors.

* For identification purpose only

Stock Code: 833330

Stock Short Name: Junshi Bio-B

Chief Agency Broker: CICC

Shanghai Junshi Biosciences Co., Ltd.**Announcement on Release of Lock-Up for Domestic Shares**

The Company and all members of the board of directors warrant that the contents of the announcement are true, accurate and complete and that there is no false and misleading statement or material omission herein, and are severally and jointly responsible for the truthfulness, accuracy and completeness of the contents herein.

I. Total Shares for the Release of Lock-up is 57,976,480, Representing 9.64% of the Total Share Capital of the Company. The Transfer Date is 27 June 2019.

The Company was also listed on the Hong Kong Stock Exchange with 182,746,500 overseas-listed foreign invested shares (H shares) in issue. The percentage in the total share capital of the Company stated above was the percentage of the number of shares released lock-up in all domestic shares (NEEQ) of the Company in issue.

II. Details and Reasons for the Release of Lock-Up for Domestic Shares (NEEQ)

Unit: Share

No.	Name of shareholder	Whether being controlling shareholder, de facto controller or party acting in concert	Whether being director, supervisor or senior management	Reasons for the Release of lock-up	Number of registered shares for release of lock-up	Percentage of number of release of lock-up in the total share capital of the Company	Number of shares not yet release of lock-up
1	Xiong Fengxiang (熊鳳祥)	Yes	Yes	A Release of lock-up for pre-listing shares by batches	57,976,480	9.64%	0
Total				–	57,976,480	9.64%	0

Note: “Percentage of number of release of lock-up in the total share capital of the Company” represents the percentage of the number of release of lock-up for domestic shares (NEEQ) by Xiong Fengxiang (熊鳳祥) in total shares of domestic shares (NEEQ) of the Company.

The application for the release of lock-up is made in accordance with relevant requirements of the Business Rules of the National Equities Exchange and Quotations System (for Trial Implementation).

Specifically as follows:

● Business Rules of the National Equities Exchange and Quotations System (for Trial Implementation)

Article 2.8 “Stocks directly or indirectly held by controlling shareholders and de facto controllers of NEEQ-listed companies before the listing shall be released from transfer restrictions in three batches at the listing date, the expiration of one year and two years from the listing date. The number of shares released from transfer restrictions for each batch is one-third of the shares held before the listing.”

Xiong Fengxiang (熊鳳祥) is one of the controlling shareholders and de facto controllers of the Company. The shares intended to be released from transfer restrictions have met the unlock conditions as stipulated in the Business Rules of the National Equities Exchange and Quotations System (for Trial Implementation).

III. Details of the Release of Lock-Up for Domestic Shares (NEEQ)

Nature of shares		Number of shares	Percentage
Shares not subject to lock-up		453,251,564	75.37%
Shares subject to lock-up	1. Senior management shares	61,940,676	10.30%
	2. Individuals or funds	71,203,112	11.83%
	3. Other entities	8,091,648	1.35%
	4. Others	6,913,000	1.15%
	Total shares subject to lock-up	148,148,436	24.63%
Total share capital		601,400,000	100.00%

Note: “Number of shares” and “Percentage” in the above table represent the number of relevant class of domestic shares and the percentage of total number of domestic shares of the Company (NEEQ), respectively. “Total share capital” represents the total number of domestic shares of the Company (NEEQ).

IV. Others

- (1) There were no outstanding undertakings made by the shareholders who applied for the release of lock-up.
- (2) There was no non-operating capital of the Company occupied by the shareholders who applied for the release of lock-up.

- (3) There were no behaviors that compromised the interest of the Company resulted from providing guarantees for the violation of the shareholders who applied for the release of lock-up.
- (4) There were shares subject to lock-up agreed and undertook by the Company and shareholders of the Company for the release of lock-up.

Shanghai Junshi Biosciences Co., Ltd.
The Board of Directors
24 June 2019